An overview of treatments for metastatic melanoma, including data updates regarding combination options.
Case: A 62-Year-Old Female with Stage IV Melanoma
This is a video synopsis/summary of a Case-Based Peer Perspectives episodefeaturing Michael B. Atkins, MD.
There are several first-line systemic therapy options for patients with BRAF-mutated metastatic melanoma. Three combinations of BRAF inhibitors (dabrafenib, encorafenib,vemurafenib) and MEK inhibitors (trametinib, binimetinib, cobimetinib) are FDA approved. They have superior response rates, progression-free survival (PFS), and overall survival compared with BRAF inhibitor monotherapy in phase 3 trials. The HRs for PFS benefit are similar, approximately 0.54-0.58. Choice of regimen is usually based on toxicities and administration needs.
Immunotherapy options include pembrolizumab or nivolumab monotherapy, with approximately 40% response rates; nivolumab plus ipilimumab, which showed a 14% PFS/overall survival (OS) benefit at 5 to 6.5 years over nivolumab alone for BRAF-mutant melanoma in the CheckMate 067 trial, suggesting this combination is preferred for eligible patients; and relatlimab plus nivolumab, which was recently approved based on the RELATIVITY-047 trial showing PFS/OS benefit over nivolumab alone in BRAF-mutant and wild-type melanoma.
With many options, key considerations are efficacy, toxicity, and administration needs.
Video synopsis is AI-generated and reviewed by Targeted Oncology® editorial staff.
RELATIVITY-047 vs CheckMate 067 Matched Cohorts in Melanoma Show Similar Efficacy
October 10th 2024During a Case-Based Roundtable® event, Ahmad Tarhini, MD, PhD, discussed the indirect comparison of ipilimumab plus nivolumab and nivolumab/relatlimab in advanced melanoma in the second article of a 2-part series.
Read More